UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $100

Benzinga Newsdesk www.benzinga.com Positive 72.5%

Neg 0% Neu 0% Pos 72.5%

UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $100.